1. Chromosomes and Gene Expression
  2. Genetics and Genomics

Control of telomere length in yeast by SUMOylated PCNA and the Elg1 PCNA unloader

  1. Pragyan Singh
  2. Inbal Gazy
  3. Martin Kupiec  Is a corresponding author
  1. The Shmunis School of Biomedicine and Cancer Research, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel
https://doi.org/10.7554/eLife.86990.3
Share this article
Cite this article
  1. Pragyan Singh
  2. Inbal Gazy
  3. Martin Kupiec
(2023)
Control of telomere length in yeast by SUMOylated PCNA and the Elg1 PCNA unloader
eLife 12:RP86990.
https://doi.org/10.7554/eLife.86990.3
  2. Download BibTeX
  3. Download .RIS

Abstract

Telomeres cap and protect the linear eukaryotic chromosomes. Telomere length is determined by an equilibrium between positive and negative regulators of telomerase activity. A systematic screen for yeast mutants that affect telomere length maintenance in the yeast Saccharomyces cerevisiae revealed that mutations in any of ~500 genes affects telomere length. One of the genes that, when mutated, causes telomere elongation is ELG1, which encodes an unloader of PCNA, the processivity factor for replicative DNA polymerases. PCNA can undergo SUMOylation on two conserved residues, K164 and K127, or ubiquitination at lysine 164. These modifications have already been implicated in genome stability processes. We report that SUMOylated PCNA acts as a signal that positively regulates telomerase activity. We also uncovered physical interactions between Elg1 and the CST (Cdc13-Stn1-Ten) complex and addressed the mechanism by which Elg1 and Stn1 negatively regulates telomere elongation, coordinated by SUMO. We discuss these results with respect to how chromosomal replication and telomere elongation are coordinated.

eLife assessment

This important study aims to discover the mechanisms governing the switch between conventional DNA replication and the specialized mechanism of telomere end replication. Solid genetic and biochemical assays suggest an interplay between sumoylated PCNA and chromosome terminal capping proteins. The questions addressed have implications for several fields, such as genome stability.

https://doi.org/10.7554/eLife.86990.3.sa0

Introduction

Telomeres cap the ends of linear eukaryotic chromosomes and safeguard them against genome instability. Telomeric DNA consists of G/C-rich DNA repeats, with the G-rich strand extending to form a 3' single-stranded overhang. Telomeres are primarily involved in counteracting the gradual shortening of the telomeric DNA caused by conventional DNA replication, thereby solving the ‘end-replication problem’ (Bonnell et al., 2021; Soudet et al., 2014). Another important function of telomeres is to protect chromosome ends from improper recognition as a DNA double-strand break (DSB) (reviewed in de Lange, 2018).

An important, conserved protein complex involved in the regulation of telomere length is the CST, which in Saccharomyces cerevisiae is composed of Cdc13, Stn1, and Ten1 (Chen and Lingner, 2013; Ge et al., 2020; Lim et al., 2020; Puglisi et al., 2008; Rice and Skordalakes, 2016). The CST has similarity to the ssDNA binding complex RPA and localizes specifically to the single-stranded telomeric DNA, where it is involved in chromosome end capping and telomere length regulation (Hughes et al., 2000; Lin and Zakian, 1996; Mersaoui and Wellinger, 2019). The CST facilitates telomerase-mediated telomere elongation (Evans and Lundblad, 1999; Evans and Lundblad, 2000; Nugent et al., 1996), participates in telomere processing during DNA replication (Soudet et al., 2014), and helps ‘capping’ the telomere (Mersaoui and Wellinger, 2019). In late S-phase, Cdc13 interacts with the Est1 subunit of telomerase and promotes telomerase activity (Chandra et al., 2001; Chen et al., 2018). Stn1 binds Cdc13 in a region that overlaps with that bound by Est1. Recruitment of Stn1 evicts Est1 and prevents further elongation of the G-strand (Chandra et al., 2001; Wang et al., 2000). The amino terminus of Stn1 binds Ten1, whereas its C-terminus interacts with both Cdc13 and Pol12, a subunit of Polymerase Alpha (Grossi et al., 2004; Petreaca et al., 2006; Puglisi et al., 2008). Thus, the CST coordinates leading strand elongation by telomerase with lagging strand DNA synthesis by the cell’s replisome (Grossi et al., 2004).

Very often the integrity of the genome is compromised by internal and external sources of DNA damage. This vulnerability increases during S-phase when the DNA is unpacked and copied. Elg1, the major subunit of a replication factor C-like complex (RLC), plays a central role in DNA replication and is critical for genome maintenance. In S. cerevisiae, loss of the ELG1 gene causes gross chromosomal rearrangements, chromosome losses, defective sister chromatid cohesion and recombination, increased sensitivity to DNA damaging agents, and abnormal telomere length maintenance (reviewed in Arbel et al., 2021). The function of the Elg1 RLC is to unload the processivity factor PCNA from chromatin, in particular after Okazaki fragment processing and ligation in the lagging strand, and during DNA repair (Kubota et al., 2015; Kubota et al., 2013; Parnas et al., 2010; Shemesh et al., 2017). The mammalian ortholog of ELG1 (ATAD5) participates in the Fanconi Anemia pathway (Kim et al., 2020; Yang et al., 2011) and, when mutated, leads to genome instability and cancer in mice and humans (Bell et al., 2011; Kuchenbaecker et al., 2015; Maleva Kostovska et al., 2016).

Post-translational modifications of PCNA (in particular ubiquitination and SUMOylation) orchestrate the activity of a large number of interacting proteins during DNA replication and repair. Many of these proteins interact through a PIP (PCNA Interacting Peptide) motif. PCNA can undergo SUMOylation on two conserved residues, K164 and K127, or ubiquitination at lysine 164. Although the Elg1 RLC shows affinity to SUMOylated PCNA, the complex is able to unload modified and unmodified versions of the clamp (Kang et al., 2019; Kubota et al., 2015; Kubota et al., 2013; Parnas et al., 2010; Shemesh et al., 2017; Shiomi and Nishitani, 2013). Thus SUMOylation may assist but is not essential for PCNA unloading. Retention and accumulation of PCNA on DNA is the major cause of genome instability in elg1Δ (Itzkovich et al., 2023; Johnson et al., 2016; Shemesh et al., 2017).

Previous studies found that telomeric proteins, and in particular the CST, can be regulated by SUMO modification (Hang et al., 2011). Here we show that SUMOylation of PCNA plays a role in the regulation of telomere length and uncovers an interaction between the Elg1 RLC and the CST. We report that PCNA SUMOylation positively regulates telomerase activity, and its unloading by the Elg1-RLC is essential for normal telomere size regulation. The N-terminus of Elg1 interacts with Stn1 during late S-phase and mediates the interaction between Stn1 and Cdc13 after PCNA has been unloaded from the telomeres.

Results

The long telomeres phenotype of elg1Δ strains requires PCNA SUMOylation

Previous results suggested that the Elg1 protein preferentially interacts with the SUMO machinery and with SUMOylated PCNA (Parnas et al., 2011; Parnas et al., 2010; Shemesh et al., 2017). To test whether PCNA modifications play any role in the elongated telomere phenotype of elg1Δ, we combined the ELG1 deletion with mutations in the POL30 gene, encoding PCNA. We mutated either lysine 127, lysine 164, or both (hereafter referred as pol30-K127R, pol30-K164R, and pol30-RR, respectively) in the elg1Δ background. Figure 1 shows that the mutations in POL30 have little effect by themselves. Importantly, whereas the single mutants did not affect the long telomeres of elg1Δ, mutating both lysine residues of each PCNA subunit completely abrogated the long telomere phenotype. Lysine 164 can be modified by both SUMO and ubiquitin; mutating only this residue prevents ubiquitination, but not SUMOylation. Figure 1 demonstrates that this mutant shows no effect. To ensure that SUMO, and not ubiquitin, is the modification responsible for the long telomeres of elg1Δ, we deleted RAD18, encoding the E3 ubiquitin ligase required to ubiquitinate PCNA (Hoege et al., 2002; Stelter and Ulrich, 2003). Figure 1 shows that lack of Rad18 has no effect on the elongated telomeres of elg1Δ. (Deletion of the SUMO E3 ligases SIZ1 and SIZ2 [to prevent SUMOylation] by itself alters telomere length [Hang et al., 2011] and thus they could not be used here.) We conclude that SUMOylation of PCNA is required for the long telomeres phenotype of elg1Δ mutants.

Figure 1
Download asset Open asset
SUMOylated PCNA regulates telomere length.

(A) Southern blot (Teloblot) showing that lack of SUMOylation of PCNA prevents telomere elongation. Independently created colonies were passaged ten times, its DNA extracted, digested with XhoI, and run in an agarose gel. The DNA was then transferred to a nitrocellulose membrane, which was incubated with a radioactive probe that detects telomeres, and a size marker. (B) Teloblot showing that overexpression of wild-type PCNA or Pol30-RR-SUMO fusion, but not Pol30-ubiquitin fusion or Pol30-RR causes telomere elongation.

Figure 1—source data 1

Source data is the original Southern blot.

https://cdn.elifesciences.org/articles/86990/elife-86990-fig1-data1-v1.zip

These results suggest that SUMOylated PCNA may play a central role in determining telomere length also in cells with wild-type Elg1 activity. We thus next asked whether artificially overexpressing modified and unmodified PCNA may mimic the long telomere phenotype of elg1Δ. Since it is hard to force ubiquitination or SUMOylation of PCNA in vivo, we used covalent fusions between PCNA and either ubiquitin or SUMO. These have been shown in the past to mimic naturally modified PCNA molecules (Parker et al., 2007; Takahashi et al., 2020). We overexpressed either wild-type Pol30, Pol30-RR (which cannot be modified) ,or Pol30-RR fused either to ubiquitin or to SUMO, in pol30-RR cells, unable to carry out modifications of the PCNA encoded by the genome. Figure 1B shows that telomeres become elongated upon overexpression of the wild-type protein (which can be modified), or the Pol30-RR version fused to SUMO, but do not elongate upon overexpression of the unmodifiable Pol30-RR version, or the one fused to ubiquitin. These results, together with those of Figure 1A, show that accumulation of SUMOylated PCNA, and not unmodified or ubiquitinated PCNA, is both necessary and sufficient for telomere elongation in the presence or in the absence of Elg1.

Genetic and physical interactions between Elg1 and Stn1

The elongated telomere phenotype of Elg1 was identified in systematic screens of the yeast knockout collection (Askree et al., 2004; Gatbonton et al., 2006), together with ~200 additional mutants of similar phenotypes. To identify the pathway of telomere length maintenance in which Elg1 participates, we systematically combined the elg1Δ mutant with all the other mutants with long telomeres. Most double mutants exhibited telomeres longer than each of the single mutants, indicating that they affect different pathways. One of the mutants showing clear epistasis (the double mutant was not longer than the single mutants) carried a deletion of RRP8, a gene involved in modification of the ribosomal RNA. Further analysis demonstrated that the knockout of RRP8 exhibited the ‘neighboring gene effect,’ and in fact the deletion of RRP8 caused a decrease in the expression of its neighboring gene, STN1 (Ben-Shitrit et al., 2012). We confirmed the genetic interactions between ELG1 and STN1 alleles by combining elg1Δ with the stn1-13 and stn1-164 alleles (Grandin et al., 1997), which exhibit long telomeres. The telomeres of the double mutants are not longer than those of the single mutants (Figure 2A), indicating that Elg1 works in the same TLM pathway as Stn1.

Figure 2
Download asset Open asset
Genetic and physical interaction between ELG1 and STN1.

(A) Teloblot showing epistasis between elg1Δ and stn1 mutants. (B) Co-Immunoprecipitation experiment showing physical interaction between Elg1 and Stn1 and reduced physical interaction between Elg1-sim and Stn1. No interaction could be detected between Elg1 and Cdc13 or Ten1.

Figure 2—source data 1

The source data contains the Southern blots and the Western blots used to make the figure.

https://cdn.elifesciences.org/articles/86990/elife-86990-fig2-data1-v1.zip

Given the epistatic relations between the ELG1 and STN1 genes, we addressed, by co-immunoprecipitation (IP) and yeast two-hybrid (YTH) assay, whether the proteins in the CST complex interact with Elg1. IP of epitope-tagged Elg1 pulled down Stn1 but not the other two members of the CST complex, Cdc13 or Ten1 (Figure 2B). For our YTH experiments, the Elg1 protein was divided into three main functional domains: an N-terminal domain (amino acids 1–234), a central AAA domain (amino acids 235–514), and a C-terminal domain (amino acids 515–791) (Itzkovich et al., 2023; Figure 3A). The AAA and C-terminal domains contain the conserved RFC boxes and are required for the interactions with the small RFC subunits, shared by all RFC-like domains. The N-terminal domain (hereafter referred to as NTD) is unique to Elg1 (Arbel et al., 2021). We thus concentrated on this domain and used the C-terminus as a negative control as it does not interact with any of the proteins tested here.

Figure 3 with 2 supplements see all
Download asset Open asset
Determinants of the Elg1-Stn1 interaction.

(A) Schematic representation of the Elg1 protein. The three SIM motifs, the WalkerA motif and the two threonines at the interface with PCNA, are shown. (B) Yeast two-hybrid (YTH) interaction of Cdc13 and Elg1 in a wild-type strain. AD: protein fused to the activating domain of Gal4; BD: protein fused to the DNA binding domain of Gal4. e.v.: empty vector. (C) YTH interaction of Stn1 and Elg1 in a wild-type strain. (D) YTH experiments in the siz1Δ siz2Δ and pol30-RR background. (E) Co-Immunoprecipitation experiment showing physical interaction between Cdc13 and PCNA.

Figure 3—source data 1

The Source data contains the Western blots used in Figure 3E.

https://cdn.elifesciences.org/articles/86990/elife-86990-fig3-data1-v1.zip

The NTD contains SUMO-interacting motifs (SIMs), which were previously shown to interact with SUMO and the SUMO machinery (Parnas et al., 2011; Parnas et al., 2010; Figure 3A). We used the YTH technique to test potential interactions between Elg1 and the CST components, and their dependency on SUMO. The N-terminus of Elg1 interacted strongly with Cdc13 and Stn1, and weakly with Ten1 (Figure 3B, C, Figure 3—figure supplement 1). In contrast, no interaction was detected with Elg1’s CTD. We could also detect interactions of Cdc13, Stn1, and Elg1’s NTD with SUMO (Figure 3). These were used as positive controls in all our experiments. Since the results with Ten1 were much weaker than those with Cdc13 and Stn1, we concentrated on these two last proteins. Below, we dissect, using YTH in various genetic backgrounds, the interactions between Elg1, Stn1, Cdc13, and PCNA. The results are also summarized in Table 1.

Table 1
Summary of all yeast two-hybrid (YTH) interactions presented.
StrainPlasmidInteraction w/Stn1Interaction w/Cdc13
Wild typeElg1-NTDYesYes
Wild typeElg1-simNoYes
siz1Δ siz2ΔElg1-NTDNoNo
pol30-RRElg1-NTDYesNo
elg1ΔElg1-NTDYesNo
elg1-simElg1-NTDYesYes
elg1-DDElg1-NTDYesNo
elg1-sim+DDElg1-NTDYesNo
elg1-WalkerAElg1-NTDYesNo
cdc13-snmElg1-NTDYesYes
Wild typeElg1-NTD-snm: no

  1. elg1-sim: mutation in the SUMO-interacting motif of Elg1; elg1-DD: TT386/7DD; elg1-sim+DD: combination of mutations in the SIM and in TT386/7; elg1-WalkerA: mutation that eliminates ATPase and unloading activity of Elg1. cdc13-snm: allele of Cdc13 that cannot be SUMOylated.

Interestingly, the interaction of Elg1’s NTD with Stn1, but not with Cdc13, was abolished when the SIM motifs (amino acids I27A, I93K, I121A, and I122A) were mutated (Figure 3B and C). We confirmed these results by co-immunoprecipitation (co-IP) (Figure 2B). These results suggest that the interaction with Stn1 is mediated by SUMOylation of a protein, whereas the interaction of Cdc13 with Elg1-NTD is independent of the SIM in the plasmid-borne copy of Elg1. We confirmed this result by deleting the genes encoding the SUMO-specific E3 enzymes, SIZ1 and SIZ2 in the genome (a double deletion is necessary, as many times each protein can compensate for the lack of the other). Figure 3D shows that indeed deletion of the genes encoding these enzymes abolishes the interaction of Stn1 and Cdc13 with Elg1’s NTD. We conclude that SUMO plays a role in mediating the Elg1-CST interactions. Since Elg1 preferentially interacts with SUMOylated PCNA (Parnas et al., 2010) and Stn1 can bind SUMO noncovalently in YTH (Figure 3C), we reckoned that SUMOylated PCNA may mediate the interaction between Stn1 and Elg1. We therefore tested whether abolishing PCNA’s SUMOylation sites in the genome (pol30-RR) had an effect on the Stn1-Elg1 interaction. We found, however, that Elg1 and Stn1 could still interact in the pol30-RR strain (Figure 3D), despite the fact that PCNA cannot become SUMOylated. Consequently, a different SUMOylated target seems to mediate the interaction between Elg1 and Stn1, or else either one of the proteins is SUMOylated. Despite numerous attempts, we were unsuccessful in observing SUMOylation of either Stn1 or Elg1.

We also noted that, despite the fact that mutation in the plasmid-borne NTD’s SIM had no effect on the interaction with Cdc13 (Figure 3B), deletion of SIZ1 and SIZ2, and mutation in the SUMOylation sites in PCNA completely abolished the interactions between Elg1’s NTD and Cdc13 (Figure 3D). This implies that PCNA SUMOylation is necessary for the interaction between Elg1 and Cdc13. We confirmed by co-IP that Cdc13 indeed physically interacts with PCNA (Figure 3E). The interaction between Cdc13 and PCNA was almost completely abolished when PCNA could not be SUMOylated (Figure 3—figure supplement 2), In summary, the interaction between Cdc13 and both PCNA and Elg1, but not that of Elg1 with Stn1, is dependent on SUMOylation of PCNA.

Elg1’s functional activity is essential for its interaction with Cdc13

When we repeated the YTH assays in a strain in which the ELG1 gene is deleted from the genome, we were surprised to see that now Cdc13 failed to interact with the plasmid-borne Elg1-NTD (Figure 4A, compare to Figure 3B). In contrast, the interaction between Stn1 and Elg1-NTD was not affected by the deletion of the genomic ELG1.

Figure 4 with 2 supplements see all
Download asset Open asset
The unloading activity of Elg1 and Cdc13 SUMOylation are necessary for the Elg1-Cdc13 interaction.

(A) Yeast-two-hybrid (YTH) experiment in a elg1Δ strain. (B) YTH experiment in a elg1-sim strain. (C) YTH experiment in a elg1-TT386/7DD strain. (D) YTH experiment in a elg1-sim+DD strain. (E) YTH experiment in a elg1-Walker AB strain. (F) Lack of interaction between cdc13-snm and Elg1 (in a wild-type strain).

Taken together, these results imply that whereas Stn1 interacts directly with the plasmid-borne Elg1-NTD, via its SIM-mediated SUMO-binding, the interaction with Cdc13 require both PCNA SUMOylation and the genomic ELG1 gene. We can envision two formal possibilities for the latter requirement: either (1) the interaction with Cdc13 requires parts of the Elg1 protein not present in the plasmid-borne NTD (e.g., the AAA or CTD domain) or (2) Elg1’s activity (e.g., PCNA unloading) may be required to facilitate the physical interaction of the NTD with Cdc13.

To distinguish between these two possibilities, we carried out YTH experiments with strains carrying different alleles of ELG1 in the genome. Three mutations were tested first: elg1-sim (mutated in amino acids I27A, I93K, I121A I122A), which does not interact with SUMO; elg1-TT386/387DD, hereafter referred to as elg1-DD, which affects the interface Elg1-PCNA (Shemesh et al., 2017); and elg1-sim+DD, an allele that combines both mutations. Whereas the SIM mutation has a very mild effect on the ability of cells to unload PCNA, and displays no phenotypes, the elg1-DD is more impaired and has a stronger phenotype, and the elg1-sim+DD allele has essentially a null phenotype, similar to that of elg1Δ, but expressing the protein at normal levels (Itzkovich et al., 2023; Shemesh et al., 2017).

We found that in strains carrying genomic elg1-DD and elg1-sim+DD alleles, Cdc13 failed to interact with plasmid borne Elg1-NTD, whereas in the elg1-sim strain the interaction was weak but clearly seen (Figure 4B–D). This observation indicates that the PCNA unloading activity of Elg1 is essential to allow the interaction between Cdc13 and the plasmid borne Elg1-NTD: this activity is high in elg1-sim mutants, intermediate in the elg1-DD strain, and is abolished by the elg1-sim+DD mutations. Note that the presence of a functional SIM at the plasmid-borne NTD is sufficient to ensure a mild interaction with Cdc13, but only if the genomic copy retains PCNA unloading activity (as in the elg1-sim mutant). On the other hand, the presence of a functional SIM in the inactive elg1-DD allele does not warrant an interaction of Elg1’s NTD (which has SIM motifs) with Cdc13. We confirmed this idea by analyzing the interaction between Cdc13 and Elg1’s NTD in another SIM-containing mutant strain devoid of PCNA unloading activity, elg1-WalkerA (KK343/4DD), which lacks ATPase and PCNA unloading activity (Itzkovich et al., 2023). This mutant expresses wild-type levels of protein, and the mutant has essentially the same phenotype of an elg1Δ allele. Figure 4E shows that no interaction between the plasmid-borne Elg1 NTD and Cdc13 could be detected despite the fact that functional SIMs are present both at the NTD and in the genome-encoded Elg1-WalkerA protein. All the mutants expressed the Elg1 protein at wild-type levels (Figure 4—figure supplement 1).

We conclude that whereas the interaction with Stn1 is direct and mediated by the SUMOylation of a protein (different from PCNA), the interaction between Elg1’s NTD and Cdc13 is indirect and can only take place after PCNA has been SUMOylated and unloaded. This suggests a model for the coordination of telomerase activity and DNA replication: the presence of SUMOylated PCNA at telomeres may serve as a positive signal for telomerase activity. Once Elg1 unloads PCNA, however, Stn1-Elg1 can bind Cdc13, ending telomerase activity. In this context, it is possible to understand the results seen in Figure 3D, showing that mutations in the SUMO E3 enzymes or in the sites of SUMOylation of PCNA, both of which prevent PCNA SUMOylation, show the same effect as the sim+DD or walkerA mutations in the genomic ELG1 copy, which prevent PCNA unloading activity.

SUMOylation of Cdc13 is needed for interaction with Elg1

Cdc13 undergoes SUMOylation, and this modification plays an essential role in the negative regulation of telomere length (Hang et al., 2011). Thus, Cdc13 is a good candidate for the target of SUMOylation required for the interaction between Elg1 and Stn1. Accordingly, mutations of the Cdc13 SUMOylation sites (cdc13-snm, ‘SUMO no more’) weaken its interaction with Stn1 and lead to elongated telomere phenotype (Hang et al., 2011). We therefore checked whether the cdc13-snm mutation affects also the interaction with Elg1. Figure 4F shows that indeed preventing SUMOylation of Cdc13 abolishes the interaction between this protein and Elg1. Note that the strain used expresses a wild type genomic copy of CDC13. Thus, SUMOylation of the plasmid-borne version of Cdc13 (i.e., in cis) is required for these interactions in the YTH assay. No effect was observed when the YTH plasmid carried a wild-type copy of CDC13, and the genomic copy was the cdc13-snm allele (Figure 4—figure supplement 2A). In summary, the N-terminus of Elg1 interacts with Cdc13 only if (1) Cdc13 can be SUMOylated (Figure 4F), (2) PCNA can be SUMOylated (Figure 3D), and (3) PCNA can be unloaded (Figure 4A, C–E).

The interaction of Elg1 with Stn1 takes place only at late S-phase

The fact that the interactions of the Elg1 NTD with Cdc13 are dependent on PCNA modification and unloading, whereas those with Stn1 are not, suggests that the interaction with Cdc13 may be mediated by, or dependent on, the interaction of Elg1 with Stn1. To further dissect this point, we divided the Stn1 protein into an NTD (first 281 amino acids) and a CTD (amino acids 282–495). The later has been shown to be the region that interacts with Cdc13 (Petreaca et al., 2007). Figure 4—figure supplement 2B shows that the NTD of Elg1 also interacts with Stn1 via its C-terminal domain, both in WT and elg1∆ strains.

Having established Stn1 as the main interactor of Elg1 in the CST complex, we next examined the interaction between these proteins throughout the cell cycle phases. We arrested a strain with tagged Elg1, Stn1, and DNA Polymerase Delta in G1 with alpha factor. Cells were released into the cell cycle and samples were taken at intervals during two cell cycles. This allowed us to map the timing of interaction between Elg1 and Stn1 proteins, and whether this interaction is codependent on the movement of replication fork. Figure 5—figure supplement 1 shows that the total level of these proteins does not change throughout the cell cycle. We immunoprecipitated Elg1 and measured the level of the other two proteins by western blot (Figure 5A–C). Pol3 was co-IPed with Elg1 strongly only during the S-phase (40–70 min, 120–140 min), whereas Stn1 was only detected in late S-phase (60–70 min, 140–160 min) for both cell cycles and was barely detected in G1 (Figure 5A–C). This pattern coincides with telomerase activity at telomeres, which is low in early to mid S-phase and peaks in late S-phase (Puglisi et al., 2008; Taggart et al., 2002).

Figure 5 with 1 supplement see all
Download asset Open asset
Timing of Elg1-Stn1 interaction.

(A) Co-IP experiment with synchronized cells. Aliquots were taken at time intervals, Elg1 was immunoprecipitated, and the level of Stn1 and Pol3 (the large subunit of DNA polymerase Delta) was monitored by western blot. Strains with single tags are shown as controls. Whole-cell extract results are shown in Figure 5—figure supplement 1. (B) Quantitation of the western shown in (A). (C) DNA content of the cells used in (A) by cell cytometry. (D) Chromatin immunoprecipitation at telomeres (Telo-ChIP) in synchronized cells showing PCNA occupancy. (E) Interaction between Stn1 and Cdc13 in a wild type and a elg1Δ strain. (F) Quantitation of three independent biological repeats of the experiment shown in (E). **p<0.001.

Figure 5—source data 1

The Source Data contains the original Western blots used to make the figure.

https://cdn.elifesciences.org/articles/86990/elife-86990-fig5-data1-v1.zip

To monitor the arrival of the replication fork to telomeres, we performed chromatin immunoprecipitation at telomeres (Telo-ChIP) in synchronized cells. Figure 5D shows that the timing of arrival of PCNA to the telomeres (60–70 min into the cell cycle) coincides with the timing of the co-IP between Elg1 and Stn1 (Figure 5A–C). Thus, our results are consistent with the idea that Elg1 moves with the replication fork, and interacts with Stn1 at the end of S-phase, when telomeres are replicated and telomerase is activated.

The interaction between Cdc13 and Stn1 is dependent on Elg1

Our YTH and IP data suggest that unlike the relationship between Cdc13 and Elg1, the interaction between Stn1 and Elg1 is direct (Figures 2 and 3). Since both Elg1 and Cdc13 bind Stn1 at its C-terminus (Figure 4—figure supplement 1 and Petreaca et al., 2007), it is possible that the absence of Elg1 may affect the interaction between the two CST members. We thus measured the co-IP of Cdc13 and Stn1 in a wild-type or an elg1Δ strain. Cells were cell-cycle synchronized in S-phase as the interaction between these two proteins was barely seen when immunoprecipitated in an asynchronous culture. When Elg1 was absent, Stn1 exhibited a strong reduction in its co-precipitation with Cdc13 (Figure 5E and F). This suggests that the interaction between Stn1 and Cdc13 is, at least partly, dependent on Elg1.

Model: Elg1 negatively regulates the telomere length by forming an interaction with the CST complex

Taken together, our results suggest the following model (Figure 6).

Following firing of the origin proximal to the telomeres at late S-phase, Elg1 moves with the fork, unloading PCNA from the lagging strand as the fork progresses (Kubota et al., 2015; Kubota et al., 2013; Shemesh et al., 2017; Figure 6A). SUMOylation of PCNA acts as a signal for the activation of telomerase (Figures 1A, B, 6B). Once Elg1 reaches the telomeres, it interacts with Stn1 (Figure 5). This interaction requires SUMOylation of Stn1 or of some other protein, which is not PCNA (Figure 3D) nor Cdc13 (Figure 4—figure supplement 1A) and could be Stn1 itself or another telomeric protein (Hang et al., 2011). The Elg1-Stn1 complex then unloads the SUMOylated PCNA at the telomeres, and Cdc13 becomes SUMOylated (Figure 6C), now interacting with Elg1-Stn1. SUMOylation of Cdc13 allows its interaction with Stn1, and presumably with Ten1 (Hang et al., 2011), creating the complete CST complex, and preventing further telomerase activity (Figure 6D). The fact that co-IP experiments detect a strong interaction with Stn1 but fail to detect an interaction with Cdc13 (Figure 2B) suggests that indeed the interaction Elg1-Cdc13 is very transient, and Elg1 leaves chromatin immediately, leaving the C-terminus of Stn1 free to interact with Cdc13. It is possible that a single ‘wave’ of SUMOylation at the telomeres coordinates PCNA unloading with the interaction between Elg1 and Cdc13. Alternatively, unloading of PCNA by Elg1 may allow the recruitment of SUMO ligases to modify Cdc13. In support for this idea, YTH interactions between Stn1 or Cdc13 with SUMO are abolished in siz1Δ siz2Δ strains (Figure 3D).

Figure 6
Download asset Open asset
Model for the role of SUMOylated PCNA and Elg1 in telomere length regulation.

(A) Cdc13 binds ssDNA at the telomeres, Elg1 moves with the replisome at the lagging strand, unloading PCNA in each Okazaki fragment. (B) Arrival of the SUMOylated PCNA at the fork to Cdc13 promotes telomerase activity. (C) Elg1 interacts with Stn1, which could be SUMOylated. Cdc13 becomes SUMOylated. Elg1 unloads PCNA and leaves telomeres. (D) Stn1 is now able to interact with Cdc13, evicting Est1 and terminating telomerase activity.

Discussion

We have presented evidence for the fact that two negative regulators of telomerase activity, Elg1 and Stn1, work in the same pathway to coordinate chromosomal DNA replication and telomere elongation. We present a model (Figure 6) in which the unloading of SUMOylated PCNA by Elg1 at telomeres facilitates the interaction between Stn1 and Cdc13 that negatively regulate telomerase activity.

This model is supported by several observations. First, the double mutants of Elg1 and Stn1 do not show increased telomere length phenotype in comparison to the single mutants, indicating that both proteins work in the same pathway that negatively regulates telomere length (Figure 2A). In addition, the interaction between Elg1 and Stn1 seems direct and occurs exclusively during the late S-phase (Figures 2B and 5A–C). This interaction is neither dependent on SUMOylation of PCNA (Figure 3D) nor on Cdc13 (Figure 4—figure supplement 1A). In contrast, the interaction between Cdc13 and Elg1 is dependent on both the SUMOylation of PCNA (Figure 3D) and of Cdc13 itself (Figure 4F). We suggest that Elg1 participates in the negative regulation of telomere length by unloading SUMOylated PCNA from the telomeres. This eliminates a positive signal for telomerase activity and causes the exchange of Est1 by Stn1 as interactor of Cdc13, effectively terminating telomerase activity (Chandra et al., 2001; Gao et al., 2007; Ge et al., 2020; Hang et al., 2011; Puglisi et al., 2008). As expected from the model, the interaction Elg1-Cdc13 is transient and cannot be detected by co-IP.

We present evidence for the fact that SUMOylated PCNA serves as a positive signal for telomere elongation (Figure 1). Preventing its unloading (by mutations in the ELG1 gene) leads to elongated telomeres, and so does PCNA overexpression, provided the protein is able to be SUMOylated, or is fused to SUMO (thus mimicking SUMOylated PCNA) (Figure 1). ELG1 is the only PCNA unloader in eukaryotes; however, it is not an essential gene, implying that there are alternative ways in which PCNA can get unloaded (either spontaneously or with the help of RFC) (Arbel et al., 2021). Once this step does take place, Stn1 can replace Est1 as Cdc13’s partner and stop the activity of telomerase, but at a longer telomere steady-state equilibrium point. This explains both the long telomere phenotype of elg1 mutants, and the fact that it is less severe than that of stn1 alleles (Figure 2). The fact that pol30-RR mutants have stable, normal-sized telomeres (Figure 1) implies that despite lacking PCNA SUMOylation, they are able to solve the ‘end replication problem.’ Our results support the notion (Maicher et al., 2017) that there are two alternative modes of telomerase: one carrying ‘basal activity,’ with minimal genetic requirements, able to maintain most telomeres at normal size, and another, ‘sustained activity,’ required for increased elongating activity (Maicher et al., 2017). Previous results have shown that the first mode does not require Rnr1, the large subunit of the ribonucleotide reductase enzyme, whereas the second depends on it (Maicher et al., 2017). Similarly, SUMOylated PCNA is only needed for the second mode of telomerase. In our experiments, the phenotype that we monitored was elongated telomeres (e.g., by deletion of ELG1 or by overexpression of PCNA) which required sustained telomerase activity. To solve the ‘end replication problem’ and maintain normal telomere length, very little telomerase activity might be needed, and even unmodified PCNA or telomeric proteins might be able to provide that basal level.

Many proteins in the cell become SUMOylated at one point or another. This modification is usually transient due to the activity of de-SUMOylases (which eliminate the modification) and STUbLs (SUMO-dependent ubiquitin ligases, which usually send the protein to degradation). It has been proposed that SUMOylation often works by targeting many physically interacting proteins together. This may be executed by the local recruitment of SUMO ligases to preassembled, co-localized protein groups. SUMOylation thus may increase their interactions, acting to increase their local concentration or effective interaction (Jentsch and Psakhye, 2013). SUMOylation of telomeric proteins seems to be one of those cases (Garg et al., 2014; Hang et al., 2011; Matmati et al., 2018; Miyagawa et al., 2014). In our model, PCNA, Cdc13, and possibly Stn1 undergo SUMOylation to ensure the proper sequence of events in the coordination between telomerase activity and chromosomal replication. Cdc13 binds Pol12, a subunit of Polymerase Alpha (Grossi et al., 2004; Petreaca et al., 2006; Puglisi et al., 2008), allowing the synthesis of the lagging strand on the newly synthesized ssDNA. Thus, the arrival of the replisome to a short telomere at the end of S-phase brings PCNA, whose SUMOylation can elicit both telomerase activity, and its subsequent repression when PCNA is unloaded by Elg1. This in turn primes synthesis of the complementary strand, thus coordinating telomere elongation with chromosomal replication.

Materials and methods

Key resources table
Reagent type (species) or resourceDesignationSource or referenceIdentifiersAdditional information
Recombinant DNA reagentpGBD424Takahashi et al., 2020Empty yeast two-hybrid vector
Recombinant DNA reagentpGBD424-Pol30Takahashi et al., 2020Overexpresses wt PCNA
Recombinant DNA reagentpGBD424-Pol30-RRTakahashi et al., 2020Overexpresses unmodifiable PCNA
Recombinant DNA reagentpGBD424-ubiquitin-Pol30-RRTakahashi et al., 2020Overexpresses unmodifiable PCNA fused to ubiquitin
Recombinant DNA reagentpGBD424-SUMO-Pol30-RRTakahashi et al., 2020Overexpresses unmodifiable PCNA fused to SUMO
Recombinant DNA reagentpGBU9Parnas et al., 2010Yeast two-hybrid vector
Strain, strain background (Saccharomyces cerevisiae MATa strain)PJ69-4AJames et al., 1996Yeast two-hybrid strain
Chemical compound, drugAlpha FactorSigma-AldrichT6901
Commercial assay or kitProtein A sepharose beadsSigma-Aldrich17-1279-01
Commercial assay or kitProtein G sepharose beadsSigma-Aldrich17-0618-01
Chemical compound, drugPronaseSigma-AldrichP5147
AntibodyAnti-HA (mouse polyclonal)Santa Cruz Biotechnologysc73921:1000
AntibodyAnti-Myc (mouse polyclonal)Santa Cruz Biotechnology9E10, SC-401:1000

Yeast strains, plasmids, and media

Request a detailed protocol

All yeast strains used are described in Table 2. All plasmids are described in Table 3. Yeast extract-peptone-dextrose (YPD) medium was prepared with a ready-to-use mixture (Formedium). Synthetic complete (SC) minimal medium was prepared with 2% dextrose (Formedium), yeast nitrogen base without amino acids (Difco), and all necessary amino acids. A 2% agar (Difco) was added for solid medium. Standard yeast genetic procedures were used to create single and double mutants. Unless stated otherwise, all experiments were carried out at 30oC.

Table 2
Yeast strains used in this study.
Strain numberNameGenotype
13237BY4741MATa his3del, leu2del, met15del, ura3del
12480BY elg1Δ::HygMXMATa his3del, leu2del, met15del, ura3del, elg1::HYG
14421BY pol30-K127RMATa his3del, leu2del, met15del, ura3del, pol30-K127R::LEU2
14425BY pol30-K164RMATa his3del, leu2del, met15del, ura3del, pol30-K164R::LEU2
14423BY pol30-KK127,164RRMATa his3del, leu2del, met15del, ura3del, pol30-RR::LEU2
14426BY pol30-K127R elg1ΔMATa his3del, leu2del, met15del, ura3del, pol30-K127R::LEU2, elg1::HYG
14430BY pol30-K164R elg1ΔMATa his3del, leu2del, met15del, ura3del, pol30-K164R::LEU2, elg1::HYG
14428BY pol30-KK127,164RR elg1ΔMATa his3del, leu2del, met15del, ura3del,pol30-RR::LEU2,elg1::HYG
14398BY rad18Δ:: KanMXMATa his3del, leu2del, met15del, ura3del, rad18::KanMX.
14401BY rad18D::KanMX elg1D::HygMXMATa his3del, leu2del, met15del, ura3del, rad18::KanMX, elg1::HYG
19606BY pol30-KK127,164RR Elg1-HAMATa his3del, leu2del, met15del, ura3del ELG1-HA-NAT pol30-KK127,164RR:HIS3
20622BY bar1 CDC13-HA ELG1-HAMATa his3del, leu2del, met15del, ura3del, bar1::LEU2, CDC13:3HA:HISMX, ELG1-HA-KanMX
18418BY STN1-Myc Elg1-HAMATa his3del, leu2del, met15del, ura3del stn1::HYG CEN LEU2 STN1-(G)9-(myc)7 ELG1-HA-KanMx
18790BY bar1 STN1-Myc ELG1-HA POL3-FLAGMATa his3del, leu2del, met15del, ura3del bar1::NatMX stn1::HYG CEN LEU2 STN1-(G)9-(myc)7 ELG1-HA-KanMx POL3-FLAG-URA3
19552BY bar1 CDC13-HA POL30-FLAGMATa his3del, leu2del, met15del ura3del, bar1:: NatMX CDC13-3HA::HISMX, POL30-FLAG::KanMX,
20625BY CDC13-HA STN1-MycMATa his3del, leu2del, met15del, ura3del, CDC13-3HA::HISMX, stn1::HYG CEN LEU2 STN1-(G)9-(myc)7,
20626BY CDC13-HA STN1-Myc elg1DMATa his3del, leu2del, met15del, ura3del,CDC13-3HA::HISMX, stn1::HYG,CEN LEU2 STN1-(G)9-(myc)7,elg1::KanMx
20623BY TEN1-FLAGMATa his3del, leu2del, met15del, ura3del trp1del Lys2del can1:: STE2pr-Sp_HIS5 ten1::KanMX, Elg1-HA-NAT CEN URA3 TEN1-(G)8-(FLAG)3
17611W303-1aMATa leu2-3, 112 ura3-1 his3-11,15, trp1-1, ade2-1, can1- 100
9842W303 elg1Δ::HygMXMATa leu2-3, 112 ura3-1 his3-11,15, trp1-1, ade2-1, can1- 100, elg1::KanMx
9551W303 stn1-13MATa leu2-3, 112 ura3-1 his3-11,15, trp1-1, ade2-1, can1- 100, stn1-13
9848W303 elg1Δ::HygMX stn1-13MATa leu2-3, 112 ura3-1 his3-11,15, trp1-1, ade2-1, can1- 100 elg1::KanMx, stn1-13
12357W303 stn1-164MATa leu2-3, 112 ura3-1 his3-11,15, trp1-1, ade2-1, can1- 100, stn1Δ::Hyg+pRS-stn1-L164A (pVL3571)
12358W303 stn1-164 elg1Δ: KanMXMATa leu2-3, 112 ura3-1 his3-11,15, trp1-1, ade2-1, can1- 100, elg1::KanMx, stn1Δ::Hyg+pRS-stn1-L164A (pVL3571)
12062PJ69-4MAT@ trp1-901 leu2-3,112 ura3-52 his3-200 gal4del gal80del GAL2-ADE2 LYS2:: GAL1-HIS3 met2::GAL7-lacZ
15017PJ elg1DMAT@ trp1-901 leu2-3,112 ura3-52 his3-200 gal4del gal80del GAL2-ADE2 LYS2:: GAL1-HIS3 met2::GAL7-lacZ elg1::HYG
19774PJ siz1 siz2MAT@ trp1-901 leu2-3,112 ura3-52 his3-200 gal4del gal80del GAL2-ADE2 LYS2:: GAL1-HIS3 met2::GAL7-lacZ siz1::KanMX siz2::HYG
11069PJ pol30-RRMAT@ trp1-901 leu2-3,112 ura3-52 his3-200 gal4del gal80del GAL2-ADE2 LYS2:: GAL1-HIS3 met2::GAL7-lacZ POL30-RR:: leu2:: KANMX
20624PJ STN1-MycMAT@ trp1-901 leu2-3,112 ura3-52 his3-200 gal4del gal80del GAL2-ADE2 LYS2:: GAL1-HIS3 met2::GAL7-lacZ elg1-sim::KanMx, stn1::HYG,CENLEU2 STN1-(G)9-(myc)7
19916PJ elg1-sim-MycMAT@ trp1-901 leu2-3,112 ura3-52 his3-200 gal4del gal80del GAL2-ADE2 LYS2:: GAL1-HIS3 met2::GAL7-lacZ elg1-SIM-MYC-KANMX
18798PJ elg1-DDMycMAT@ trp1-901 leu2-3,112 ura3-52 his3-200 gal4del gal80del GAL2-ADE2 LYS2:: GAL1-HIS3 met2::GAL7-lacZ elg1-DD-MYC-KANMX
19917PJ elg1-DD+sim-MycMAT@ trp1-901 leu2-3,112 ura3-52 his3-200 gal4del gal80del GAL2-ADE2 LYS2:: GAL1-HIS3 met2::GAL7-lacZ elg1-DDsim-MYC-KANMX
19915PJ elg1-Walker AMAT@ trp1-901 leu2-3,112 ura3-52 his3-200 gal4del gal80del GAL2-ADE2 LYS2:: GAL1-HIS3 met2::GAL7-lacZ, elg1 KK343/4DD:MYC:KanMX
19486PJ cdc13-snmMAT@ trp1-901 leu2-3,112 ura3-52 his3-200 gal4del gal80del GAL2-ADE2 LYS2:: GAL1-HIS3 met2::GAL7-lacZ cdc13-snm
Table 3
Plasmids used in this study.
Strain numberGenotypeSource or reference
4239pGad424 (LEU2)Kupiec lab
4238pGad424-POL30Helle Ulrich lab
4237pGad424-pol30-k127r,k164rHelle Ulrich lab
4236pGad424-pol30-k127r,k164r-SMT3Helle Ulrich lab
4235pGAD424-pol30-k127r,k164r-UBIHelle Ulrich lab
4147CEN LEU2 STN1-(G)9-(myc)7Victoria Lundblad lab
4144CEN URA3 TEN1-(G)8-(FLAG)3Victoria Lundblad lab
2201pCN181 pACT2-STN1 (LEU2)Constance Nugent lab
2205pVL855 pACT2-CDC13Constance Nugent lab
2168pACT2 - TEN1Michel Charbonneau lab
1775pGBU9 (URA3)Kupiec lab
1973pGBU9-ELG1-NTD(1-234)This study
3301pGBU9-ELG1-CTD(541-791)This study
2260pGBU9-ELG1-NTDsim(1-234)This study
2241pGBU9-SMT3This study
2419pGAD424-Stn1-Nt(1-282)David Shore lab
2420pGAD424-Stn1-Ct(282-494)David Shore lab
2169pGAD424-Stn1-13Michel Charbonneau lab
2418pGAD424-Stn1-63David Shore lab
4287pACT-cdc13-snmThis study

PCNA overexpression

Request a detailed protocol

The high copy number pGAD424 plasmid alone, or carrying the wild-type POL30, the mutant pol30-KK127,164RR (pol30-RR), or the pol30-RR fused to ubiquitin or to SUMO (Parker et al., 2007; Takahashi et al., 2020) were transformed into pol30-RR strains and grown under selective conditions.

Southern teloblots

Request a detailed protocol

For each genotype, at least three independently created strains were tested after 10 consecutive passages on YPD plates (Harari and Kupiec, 2018; Harari et al., 2013; Harari et al., 2017; Rubinstein et al., 2014). Genomic DNA was isolated by pelleting 15 ml saturated overnight yeast culture grown in YPD, then beating the cells using 0.5 mm glass beads in 500 μl lysis buffer and 500 μl phenol chloroform. Cells were spun down for 10 min at 14,000 rpm, and ∼500 μl of the top clear solution, containing the genomic DNA, was carefully taken out. DNA was precipitated using 1000 μl of 95% ethanol and then pelleted. The supernatant was discarded, and 500 μl of 70% ethanol was added. Pellets were left to dry before resuspension in 300 μl TE with RNaseA for 10 min at 65°C. The DNA was precipitated by adding 130 μl of 7.5 M ammonium acetate (pH 7) and 1 ml of 95% ethanol at −20°C, spun, and resuspended in 50 μl of TE. About 10 μl of genomic DNA was digested using XhoI overnight at 37°C. Digested gDNA and ladder were loaded onto a 0.8% agarose gel and electrophoresed overnight at ∼67 V in 1× TBE. The gel was denatured for 30 min in a rocking shaker (1.5 M NaCl, 0.5 M NaOH) and was neutralized for 15 min (1.5 M NaCl, 0.5 M Tris, pH 7.0). The DNA on the gel was transferred onto a hybond nylon membrane (GE Healthcare GERPN303B) with 10× SSC (1.5 M NaCl 0.17 M NaCitrate, dihydrate) and UV cross-linked before blocking in Church buffer (0.5 M Na2HPO4, pH 7.2, 7% SDS, 1 mM EDTA, 1% BSA) for ∼2 hr at 65°C. 32P radiolabeled PCR fragments were added onto the membrane and left to incubate overnight. The membrane was washed 3–4 times for 15 min each, with 1× SSC 0.1%SDS buffer before drying and exposing it to X-ray film. The teloblots blots were exposed for 1–8 d at –70°C before the film was developed.

Telomeric probe

Request a detailed protocol

S. cerevisiae-specific telomeric probe was labeled by random priming of 20–25 ng of a telomeric fragment and of 20–25 ng of size-control fragments using the DNA labeling mix from Biological Industries. Both fragments were generated by PCR using the primers indicated below. For the telomeric probe, a specific region of the left telomere of chromosome VII was amplified to generate a product 370 bp long. As size-control probe, a specific region of chromosome II was amplified to generate a product 1100 bp long. Since it contains an XhoI site, the size-control probe detects two bands in the sizes of 2044 bp, 779 bp in the Southern blot.

The primers for the Y' element product are

  • Y' element forward: GTTGGAGTTTTTCAGCGTTTGC

  • Y' element reverse: TGTGAACCGCTACCATCAGC

  • The Y' element PCR product is ~370 bp

  • The primers for the control product are:

  • Tel control forward: TTGTAGGGGCCTTTTGTAATGT

  • Tel control reverse: GTGCGCCCAGTAAGGGGT

  • The control PCR product is ~1100 bp

Telomere length was determined using TelQuant (Rubinstein et al., 2014).

Yeast two-hybrid

Request a detailed protocol

The yeast two-hybrid assays were performed using PJ69-4A (James et al., 1996) strains cotransformed with a LEU2-marked plasmid containing genes fused to the GAL4 activating domain (pACT or pGAD424) and a URA3- marked plasmid containing genes fused to the GAL4 DNA binding domain (pGBU9). Strains containing the test plasmids were grown for 24 hr at 30°C in SC-Ura-Leu liquid medium and were plated on the reporter maker SC-His medium.

Protein extraction and immunoprecipitation (IP) assays

Request a detailed protocol

Cells were grown to mid-logarithmic phase, washed once with water, and resuspended in lysis buffer (20 mm Tris-HCl, pH 7.5, 0.5 mm EGTA, 0.5 mm EDTA, 1 mm DTT, 125 mm potassium acetate, 12.5% glycerol, 0.1% Triton X-100, protease inhibitor mixture, and 1 mm phenylmethylsulfonyl fluoride). Cells were broken for 45 min with glass beads, centrifuged for 10 min at 10,000 × g, and the supernatant was collected. 20–30 μg of total protein extract was resolved on SDS-PAGE using 10% acrylamide gels. For immunoprecipitation, 1000 μg of proteins were prepared and pre-cleared with 20 μl of protein A-Sepharose and protein G-Sepharose beads mixture (GE Healthcare). 2 μl of (HA, Santa Cruz Biotechnology [sc7392; 1:1000] or MYC, Santa Cruz Biotechnology [9E10, SC-40; 1:1000]) antibodies were added to the cleared extract and incubated overnight at 4°C. The beads were washed once with lysis buffer, once with lysis buffer containing 0.5 m NaCl, and twice with buffer A (50 mm Tris-HCl, pH 7.5, 0.1 mm EGTA, 0.1% β-mercaptoethanol). The resulting immunoprecipitates were used for in vitro kinase assays.

Western blotting

Request a detailed protocol

Cells were collected by centrifugation, resuspended in 600 ul of phosphate-buffered saline with 1% Triton X-100 (PBST), supplemented with a protease inhibitor cocktail (Roche), and subjected to mechanical rupture using glass beads. The cell debris were removed by centrifugation, and the supernatants were applied onto 0.1 M dithiothreitol, and incubated at 80°C for 10 min before sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (resolving gel: 30% acrylamide, 1.5 M Tris-HCl pH 8.8, 10% SDS [pH 7.2], 9.7 ml H2O, 100 ul 10% APS, and 10 ul TEMED; stacking gel: 30% bis/acrylamide, 1 M Tris-HCl pH 6.8, 10% SDS [pH 7.2], 5.5 ml H2O, 800 ul 10% APS, and 8 ul TEMED). The samples were run with SDS-PAGE buffer at 100 V until the samples have passed the stacking gel and then at 160 V until the samples have been fully separated. Transfer to nitrocellulose was done in transfer buffer (200 ml methanol, 3.03 g Tris base, 14.4 g glycine) at 500 mAmp and verified by staining with Ponceau-S dye. The blot was blocked with Milk for at least 60 min at room temperature. Primary antibody was added for 12 hr at 4°C. The blot was washed 3 × 5 min with TBST (Tris-buffered saline Tween-20) and secondary antibody was added for 1 hr. The blot was washed 3 × 5 min with TBST and subjected to electro-chemiluminiscence.

Cell cycle synchronization

Request a detailed protocol

To assay Elg1 and Stn1 interaction during the cell cycle, the triple-tagged strain was grown in YPD to OD600 0.6–0.8, followed by the addition of 500 ng/ml α factor and was grown until ∼90% of the cells appeared unbudded or exhibit Shmoo formation (for ∼2 hr). The α-factor was removed by centrifugation and washing cells 2–3 times with warm YPD. Cells were released into YPD at OD600 0.6–0.8 with addition of pronase at a final concentration of 0.1 mg/ml. Cells were collected for both FACS and western blot analysis at different time points after release. Cells for FACS analysis were fixed in 70% ethanol, digested with RNase overnight, washed again and stained with propidium iodide (15 μg/ml), and analyzed by flow cytometry.

Flow cytometry

Request a detailed protocol

200 µl of a logarithmic cell culture (0.6 OD600) were harvested, resuspended in 60 µl of 50 mM Tris pH 7.5, and 140 µl of ethanol was added; cells were then kept overnight at 4°C. Fixed cells were centrifuged and washed once in 200 µl of 50 mM Tris pH 7.5 buffer and resuspended in 100 µl RNAse (0.2 mg/ml in 50 mM Tris pH 7.5) for 2 hr at 37°C. In addition, proteinase-K (0.2 mg/ml in 50 mM Tris pH 7.5) was added to each tube and cells were incubated for 60 additional minutes at 50°C. 20 µl of the sample was taken into a new tube and a 180 µl of 18 µg/ml propidium iodide 50 mM Tris pH 7.5 was added. The samples were kept in the dark at 4°C overnight, sonicated twice at low setting (20% power) for 3–5 s, and stored in the dark at 4°C. The flow cytometry MACSQuant system was used for reading. Results were analyzed using either the Flowing Software or the FlowJo program.

Chromatin immunoprecipitation

Request a detailed protocol

50 ml of each strain were grown to OD600 ≈ 1 in YPD. 1.5 ml formaldehyde (37% solution) was added for 15 min, and the formaldehyde was quenched with 2.5 ml of 2.5 M glycine for 5 min. Cells were harvested, washed once with 15 ml cold PBS, and broken down for 10 min with glass beads in 600 μl lysis buffer (50 mM HEPES-KOH pH 7.5, 140 mM NaCl, 1 mM EDTA, 1% Triton X100, 0.1% Na-deoxycholic acid). The supernatant (lysate) was removed to a new tube. The glass beads were washed with 500 μl lysis buffer, centrifuged, and the supernatant was added to the lysate. The lysate was sonicated 6–8 times for 10–15 s at 80% amplitude with 1 min on ice between each time. The sonicated material was centrifuged for 20 min at 2500 rpm. The supernatant was used for immunoprecipitations (IP). The sonicated proteins were pre-cleared with a 25 μl protein A sepharose and protein G sepharose beads mixture (GE Healthcare), and the appropriate antibodies were added to the cleared extract and incubated overnight at 4°C. PCNA were immunoprecipitated with 2–5 μg of anti-PCNA antibody (Sigma). A total of 10% of the extract was saved as input. The beads after the IP were washed once with lysis buffer, once with lysis buffer with 360 mM NaCl, once with washing buffer (10 mM Tris/HCl pH 8, 0.25 M LiCl, 0.5% NP40, 0.5% Na-deoxycholic acid, 1 mM EDTA), and once with TE (10 mM Tris/HCl pH 8 and 10 mM EDTA). The washed beads and the input were treated with elution buffer (50 mM Tris/HCl pH 8, 10 mM EDTA, 1% SDS) overnight at 65°C. The DNA was precipitated, resuspended in water, and used for PCR real-time analysis (ABI StepOnePlus Real-Time PCR System); primer concentration and cycles number were calibrated individually for each reaction. All experiments are plotted as the average of at least three independent biological repeats, and each biological repeat is the average of three technical PCR repeats. The oligonucleotides used are

  • Y′-element 5′-GGCTTGATTTGGCAAACGTT-3′

  • 5′-GTGAACCGCTACCATCAGCAT-3′

Materials availability

Request a detailed protocol

All materials in this article can be available upon contact with the corresponding author.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting file; Source Data files have been provided for Figures 1A, 1B, 2A, 2B, 3E, 4-Suppl. 1, 5A, 5E, 5-Suppl. 1.

References

    1. Kuchenbaecker KB
    2. Ramus SJ
    3. Tyrer J
    4. Lee A
    5. Shen HC
    6. Beesley J
    7. Lawrenson K
    8. McGuffog L
    9. Healey S
    10. Lee JM
    11. Spindler TJ
    12. Lin YG
    13. Pejovic T
    14. Bean Y
    15. Li Q
    16. Coetzee S
    17. Hazelett D
    18. Miron A
    19. Southey M
    20. Terry MB
    21. Goldgar DE
    22. Buys SS
    23. Janavicius R
    24. Dorfling CM
    25. van Rensburg EJ
    26. Neuhausen SL
    27. Ding YC
    28. Hansen TVO
    29. Jønson L
    30. Gerdes A-M
    31. Ejlertsen B
    32. Barrowdale D
    33. Dennis J
    34. Benitez J
    35. Osorio A
    36. Garcia MJ
    37. Komenaka I
    38. Weitzel JN
    39. Ganschow P
    40. Peterlongo P
    41. Bernard L
    42. Viel A
    43. Bonanni B
    44. Peissel B
    45. Manoukian S
    46. Radice P
    47. Papi L
    48. Ottini L
    49. Fostira F
    50. Konstantopoulou I
    51. Garber J
    52. Frost D
    53. Perkins J
    54. Platte R
    55. Ellis S
    56. Godwin AK
    57. Schmutzler RK
    58. Meindl A
    59. Engel C
    60. Sutter C
    61. Sinilnikova OM
    62. Damiola F
    63. Mazoyer S
    64. Stoppa-Lyonnet D
    65. Claes K
    66. De Leeneer K
    67. Kirk J
    68. Rodriguez GC
    69. Piedmonte M
    70. O’Malley DM
    71. de la Hoya M
    72. Caldes T
    73. Aittomäki K
    74. Nevanlinna H
    75. Collée JM
    76. Rookus MA
    77. Oosterwijk JC
    78. Tihomirova L
    79. Tung N
    80. Hamann U
    81. Isaccs C
    82. Tischkowitz M
    83. Imyanitov EN
    84. Caligo MA
    85. Campbell IG
    86. Hogervorst FBL
    87. Olah E
    88. Diez O
    89. Blanco I
    90. Brunet J
    91. Lazaro C
    92. Pujana MA
    93. Jakubowska A
    94. Gronwald J
    95. Lubinski J
    96. Sukiennicki G
    97. Barkardottir RB
    98. Plante M
    99. Simard J
    100. Soucy P
    101. Montagna M
    102. Tognazzo S
    103. Teixeira MR
    104. Pankratz VS
    105. Wang X
    106. Lindor N
    107. Szabo CI
    108. Kauff N
    109. Vijai J
    110. Aghajanian CA
    111. Pfeiler G
    112. Berger A
    113. Singer CF
    114. Tea M-K
    115. Phelan CM
    116. Greene MH
    117. Mai PL
    118. Rennert G
    119. Mulligan AM
    120. Tchatchou S
    121. Andrulis IL
    122. Glendon G
    123. Toland AE
    124. Jensen UB
    125. Kruse TA
    126. Thomassen M
    127. Bojesen A
    128. Zidan J
    129. Friedman E
    130. Laitman Y
    131. Soller M
    132. Liljegren A
    133. Arver B
    134. Einbeigi Z
    135. Stenmark-Askmalm M
    136. Olopade OI
    137. Nussbaum RL
    138. Rebbeck TR
    139. Nathanson KL
    140. Domchek SM
    141. Lu KH
    142. Karlan BY
    143. Walsh C
    144. Lester J
    145. Hein A
    146. Ekici AB
    147. Beckmann MW
    148. Fasching PA
    149. Lambrechts D
    150. Van Nieuwenhuysen E
    151. Vergote I
    152. Lambrechts S
    153. Dicks E
    154. Doherty JA
    155. Wicklund KG
    156. Rossing MA
    157. Rudolph A
    158. Chang-Claude J
    159. Wang-Gohrke S
    160. Eilber U
    161. Moysich KB
    162. Odunsi K
    163. Sucheston L
    164. Lele S
    165. Wilkens LR
    166. Goodman MT
    167. Thompson PJ
    168. Shvetsov YB
    169. Runnebaum IB
    170. Dürst M
    171. Hillemanns P
    172. Dörk T
    173. Antonenkova N
    174. Bogdanova N
    175. Leminen A
    176. Pelttari LM
    177. Butzow R
    178. Modugno F
    179. Kelley JL
    180. Edwards RP
    181. Ness RB
    182. du Bois A
    183. Heitz F
    184. Schwaab I
    185. Harter P
    186. Matsuo K
    187. Hosono S
    188. Orsulic S
    189. Jensen A
    190. Kjaer SK
    191. Hogdall E
    192. Hasmad HN
    193. Azmi MAN
    194. Teo S-H
    195. Woo Y-L
    196. Fridley BL
    197. Goode EL
    198. Cunningham JM
    199. Vierkant RA
    200. Bruinsma F
    201. Giles GG
    202. Liang D
    203. Hildebrandt MAT
    204. Wu X
    205. Levine DA
    206. Bisogna M
    207. Berchuck A
    208. Iversen ES
    209. Schildkraut JM
    210. Concannon P
    211. Weber RP
    212. Cramer DW
    213. Terry KL
    214. Poole EM
    215. Tworoger SS
    216. Bandera EV
    217. Orlow I
    218. Olson SH
    219. Krakstad C
    220. Salvesen HB
    221. Tangen IL
    222. Bjorge L
    223. van Altena AM
    224. Aben KKH
    225. Kiemeney LA
    226. Massuger LFAG
    227. Kellar M
    228. Brooks-Wilson A
    229. Kelemen LE
    230. Cook LS
    231. Le ND
    232. Cybulski C
    233. Yang H
    234. Lissowska J
    235. Brinton LA
    236. Wentzensen N
    237. Hogdall C
    238. Lundvall L
    239. Nedergaard L
    240. Baker H
    241. Song H
    242. Eccles D
    243. McNeish I
    244. Paul J
    245. Carty K
    246. Siddiqui N
    247. Glasspool R
    248. Whittemore AS
    249. Rothstein JH
    250. McGuire V
    251. Sieh W
    252. Ji B-T
    253. Zheng W
    254. Shu X-O
    255. Gao Y-T
    256. Rosen B
    257. Risch HA
    258. McLaughlin JR
    259. Narod SA
    260. Monteiro AN
    261. Chen A
    262. Lin H-Y
    263. Permuth-Wey J
    264. Sellers TA
    265. Tsai Y-Y
    266. Chen Z
    267. Ziogas A
    268. Anton-Culver H
    269. Gentry-Maharaj A
    270. Menon U
    271. Harrington P
    272. Lee AW
    273. Wu AH
    274. Pearce CL
    275. Coetzee G
    276. Pike MC
    277. Dansonka-Mieszkowska A
    278. Timorek A
    279. Rzepecka IK
    280. Kupryjanczyk J
    281. Freedman M
    282. Noushmehr H
    283. Easton DF
    284. Offit K
    285. Couch FJ
    286. Gayther S
    287. Pharoah PP
    288. Antoniou AC
    289. Chenevix-Trench G
    290. EMBRACE
    291. GEMO Study Collaborators
    292. Breast Cancer Family Registry
    293. HEBON
    294. KConFab Investigators
    295. Australian Cancer Study (Ovarian Cancer Investigators)
    296. Australian Ovarian Cancer Study Group
    297. Consortium of Investigators of Modifiers of BRCA1 and BRCA2
    (2015) Identification of six new susceptibility loci for invasive epithelial ovarian cancer
    Nature Genetics 47:164–171.
    https://doi.org/10.1038/ng.3185

Article and author information

Author details

  1. Pragyan Singh

    The Shmunis School of Biomedicine and Cancer Research, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    Contribution
    Conceptualization, Formal analysis, Investigation, Writing – original draft
    Competing interests
    No competing interests declared

  2. Inbal Gazy

    The Shmunis School of Biomedicine and Cancer Research, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    Contribution
    Conceptualization, Formal analysis, Investigation
    Competing interests
    No competing interests declared

  3. Martin Kupiec

    The Shmunis School of Biomedicine and Cancer Research, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    Contribution
    Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Writing – original draft, Project administration, Writing – review and editing
    For correspondence
    martin@tauex.tau.ac.il
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7934-3342

Funding

Israel Science Foundation (1105/19)

  • Martin Kupiec

Israel Cancer Research Fund (408)

  • Martin Kupiec

Recanati Fund (23)

  • Martin Kupiec

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We thank David Shore, Hele Ulrich, Connie Nugent, Michel Charboneau, and Vicky Lundblad for strains and plasmids. We thank all present and past members of the Kupiec lab for support and ideas, and Ofir Hurvitz for help during the first stages of this project. This research was supported by grants from the Israel Science Foundation, the Israel Cancer Research Fund, and the Recanati Fund.

Version history

  1. Preprint posted: February 22, 2023 (view preprint)
  2. Sent for peer review: February 22, 2023
  3. Preprint posted: May 5, 2023 (view preprint)
  4. Preprint posted: July 17, 2023 (view preprint)
  5. Version of Record published: August 2, 2023 (version 1)

Cite all versions

You can cite all versions using the DOI https://doi.org/10.7554/eLife.86990. This DOI represents all versions, and will always resolve to the latest one.

Copyright

© 2023, Singh et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 718
    views
  • 66
    downloads
  • 1
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Pragyan Singh
  2. Inbal Gazy
  3. Martin Kupiec
(2023)
Control of telomere length in yeast by SUMOylated PCNA and the Elg1 PCNA unloader
eLife 12:RP86990.
https://doi.org/10.7554/eLife.86990.3

Share this article

https://doi.org/10.7554/eLife.86990

Categories and tags

Research organism

Further reading

    1. Chromosomes and Gene Expression
    2. Developmental Biology

    Dynamic modes of Notch transcription hubs conferring memory and stochastic activation revealed by live imaging the co-activator Mastermind

    F Javier DeHaro-Arbona, Charalambos Roussos ... Sarah Bray
    Research Article

    Developmental programming involves the accurate conversion of signalling levels and dynamics to transcriptional outputs. The transcriptional relay in the Notch pathway relies on nuclear complexes containing the co-activator Mastermind (Mam). By tracking these complexes in real time, we reveal that they promote the formation of a dynamic transcription hub in Notch ON nuclei which concentrates key factors including the Mediator CDK module. The composition of the hub is labile and persists after Notch withdrawal conferring a memory that enables rapid reformation. Surprisingly, only a third of Notch ON hubs progress to a state with nascent transcription, which correlates with polymerase II and core Mediator recruitment. This probability is increased by a second signal. The discovery that target-gene transcription is probabilistic has far-reaching implications because it implies that stochastic differences in Notch pathway output can arise downstream of receptor activation.

    1. Chromosomes and Gene Expression

    The role of RNA in the maintenance of chromatin domains as revealed by antibody mediated proximity labelling coupled to mass spectrometry

    Rupam Choudhury, Anuroop Venkateswaran Venkatasubramani ... Axel Imhof
    Research Article

    Eukaryotic chromatin is organized into functional domains, that are characterized by distinct proteomic compositions and specific nuclear positions. In contrast to cellular organelles surrounded by lipid membranes, the composition of distinct chromatin domains is rather ill described and highly dynamic. To gain molecular insight into these domains and explore their composition, we developed an antibody-based proximity-biotinylation method targeting the RNA and proteins constituents. The method that we termed Antibody-Mediated-Proximity-Labelling-coupled to Mass Spectrometry (AMPL-MS) does not require the expression of fusion proteins and therefore constitutes a versatile and very sensitive method to characterize the composition of chromatin domains based on specific signature proteins or histone modifications. To demonstrate the utility of our approach we used AMPL-MS to characterize the molecular features of the chromocenter as well as the chromosome territory containing the hyperactive X-chromosome in Drosophila. This analysis identified a number of known RNA binding proteins in proximity of the hyperactive X and the centromere, supporting the accuracy of our method. In addition, it enabled us to characterize the role of RNA in the formation of these nuclear bodies. Furthermore, our method identified a new set of RNA molecules associated with the Drosophila centromere. Characterization of these novel molecules suggested the formation of R-loops in centromeres, which we validated using a novel probe for R-loops in Drosophila. Taken together, AMPL-MS improves the selectivity and specificity of proximity ligation allowing for novel discoveries of weak protein-RNA interactions in biologically diverse domains.

    1. Cancer Biology
    2. Chromosomes and Gene Expression

    Ribosome subunit attrition and activation of the p53–MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition

    Gregory Caleb Howard, Jing Wang ... William P Tansey
    Research Article

    The chromatin-associated protein WD Repeat Domain 5 (WDR5) is a promising target for cancer drug discovery, with most efforts blocking an arginine-binding cavity on the protein called the ‘WIN’ site that tethers WDR5 to chromatin. WIN site inhibitors (WINi) are active against multiple cancer cell types in vitro, the most notable of which are those derived from MLL-rearranged (MLLr) leukemias. Peptidomimetic WINi were originally proposed to inhibit MLLr cells via dysregulation of genes connected to hematopoietic stem cell expansion. Our discovery and interrogation of small-molecule WINi, however, revealed that they act in MLLr cell lines to suppress ribosome protein gene (RPG) transcription, induce nucleolar stress, and activate p53. Because there is no precedent for an anticancer strategy that specifically targets RPG expression, we took an integrated multi-omics approach to further interrogate the mechanism of action of WINi in human MLLr cancer cells. We show that WINi induce depletion of the stock of ribosomes, accompanied by a broad yet modest translational choke and changes in alternative mRNA splicing that inactivate the p53 antagonist MDM4. We also show that WINi are synergistic with agents including venetoclax and BET-bromodomain inhibitors. Together, these studies reinforce the concept that WINi are a novel type of ribosome-directed anticancer therapy and provide a resource to support their clinical implementation in MLLr leukemias and other malignancies.